Literature DB >> 7521270

Diagnostic and therapeutic applications of angiogenesis research.

J Folkman1.   

Abstract

Certain principles of the angiogenic process elucidated in the laboratory over the past 3 decades have now been translated to clinical application. These applications are in the areas of prognosis, inhibition of angiogenesis, and acceleration of angiogenesis. As more experience is gained from these studies we may begin to see the development of therapies for many other angiogenic diseases, including diabetic retinopathy, rheumatoid arthritis, and psoriasis. It may be possible to increase the rate of neovascularization of a myocardial infarction and perhaps even to stimulate the growth of coronary collateral vessels. From these laboratory and clinical studies it has become clear that angiogenesis is a fundamental process that dominates diseases in many different branches of medicine and surgery. A clear understanding of the biological and molecular aspects of this process will be critical to the successful treatment of a wide spectrum of "angiogenic diseases" [53].

Entities:  

Mesh:

Year:  1993        PMID: 7521270

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  11 in total

Review 1.  Spatiotemporal control over growth factor signaling for therapeutic neovascularization.

Authors:  Lan Cao; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2007-08-16       Impact factor: 15.470

2.  Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin).

Authors:  G B Thurman; D L Page; B D Wamil; L E Wilkinson; M Kasami; C G Hellerqvist
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas.

Authors:  M Berard; S Sordello; N Ortega; J L Carrier; N Peyri; M Wassef; N Bertrand; O Enjolras; L Drouet; J Plouet
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

4.  Anti-Tumorigenic Potential of a Novel Orlistat-AICAR Combination in Prostate Cancer Cells.

Authors:  Clayton Wright; Anand Krishnan V Iyer; Vivek Kaushik; Neelam Azad
Journal:  J Cell Biochem       Date:  2017-05-23       Impact factor: 4.429

5.  In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to alpha(v)beta3 integrin localization.

Authors:  B Vailhé; X Ronot; P Tracqui; Y Usson; L Tranqui
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997 Nov-Dec       Impact factor: 2.723

6.  In vivo toxicity studies of europium hydroxide nanorods in mice.

Authors:  Chitta Ranjan Patra; Soha S Abdel Moneim; Enfeng Wang; Shamit Dutta; Sujata Patra; Michal Eshed; Priyabrata Mukherjee; Aharon Gedanken; Vijay H Shah; Debabrata Mukhopadhyay
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-17       Impact factor: 4.219

7.  PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.

Authors:  Laetitia Devy; Shafaat A Rabbani; Mark Stochl; Mary Ruskowski; Ian Mackie; Laurent Naa; Mark Toews; Reinoud van Gool; Jie Chen; Art Ley; Robert C Ladner; Daniel T Dransfield; Paula Henderikx
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

8.  Immunocytochemical Investigations on the Vascularization of Pituitary Adenomas.

Authors:  Marek Pawlikowski; Hanna Pisarek; Maria Jaranowska
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

9.  Circulating Natural IgM Antibodies Against Angiogenin in the Peripheral Blood Sera of Patients with Osteosarcoma as Candidate Biomarkers and Reporters of Tumorigenesis.

Authors:  Yulia A Savitskaya; Genaro Rico; Luis Linares; Roberto González; René Téllez; Eréndira Estrada; Norma Marín; Elisa Martínez; Alfonso Alfaro; Clemente Ibarra
Journal:  Biomark Cancer       Date:  2010-11-28

10.  Ig-like domain 6 of VCAM-1 is a potential therapeutic target in TNFα-induced angiogenesis.

Authors:  Taek-Keun Kim; Chang Sik Park; Hee-Jun Na; Kangseung Lee; Aerin Yoon; Junho Chung; Sukmook Lee
Journal:  Exp Mol Med       Date:  2017-02-17       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.